BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32422252)

  • 1. Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia.
    Wright R; Oremek M; Davies D; Kewley C; Singh A; Taitt N; Kempshall E; Wilson K; Ingram W
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1527-1533. PubMed ID: 32422252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
    Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study.
    Valkova V; Jircikova J; Trnkova M; Steinerova K; Keslova P; Lanska M; Koristek Z; Raida L; Krejci M; Kruntoradova K; Dolezal T; Benesova K; Cetkovsky P; Trneny M
    Neoplasma; 2016; 63(5):743-51. PubMed ID: 27468878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.
    Michelis FV; Messner HA; Uhm J; Alam N; Lambie A; McGillis L; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):e73-81. PubMed ID: 25458081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation: A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5.
    Kurosawa S; Yamaguchi T; Mori A; Tsukagoshi M; Okuda I; Ikeda M; Fuji S; Yamashita T; Ogawa C; Ito A; Tanaka T; Inamoto Y; Kim SW; Fukuda T
    Transplant Cell Ther; 2021 Nov; 27(11):935.e1-935.e9. PubMed ID: 34371214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
    Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Middeke JM; Kollinger F; Baldauf H; Stölzel F; Wermke M; von Bonin M; Sockel K; Link CS; Teipel R; Röllig C; Thiede C; Platzbecker U; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1947-1951. PubMed ID: 29793046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34
    Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
    Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant.
    Fernández-Caballero M; Jiménez Lorenzo MJ; Morgades de la Fe M; Ferrà Coll C; Vives Polo S; Abril Sabater L; Navarro Ferrando JT; Ribera Santasusana JM
    Med Clin (Barc); 2022 May; 158(10):451-457. PubMed ID: 34404519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Ringdén O; Boumendil A; Labopin M; Canaani J; Beelen D; Ehninger G; Niederwieser D; Finke J; Stelljes M; Gerbitz A; Ganser A; Kröger N; Kantz L; Brecht A; Savani B; Sadeghi B; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1975-1983. PubMed ID: 31181255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Recipient Health-Related Quality of Life and Donor-Recipient Relationship following Sibling Pediatric Hematopoietic Stem Cell Transplantation.
    Zając-Spychała O; Pieczonka A; Barańska M; Wachowiak J
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):401-406. PubMed ID: 31622770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.
    Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
    Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.
    Shouval R; Fein JA; Shouval A; Danylesko I; Shem-Tov N; Zlotnik M; Yerushalmi R; Shimoni A; Nagler A
    Blood Adv; 2019 Jun; 3(12):1881-1890. PubMed ID: 31221661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.
    Backhaus D; Brauer D; Pointner R; Bischof L; Vucinic V; Franke GN; Niederwieser D; Platzbecker U; Jentzsch M; Schwind S
    Bone Marrow Transplant; 2023 Jan; 58(1):30-38. PubMed ID: 36195769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.